Company intelligence / Profile preview

WellO2

Ownership: Private
Development stage: Commercial

Overview

The WellO2 device has been clinically proven to support respiratory health by opening airways, strengthening lung muscles, reducing symptoms of asthma and sleep apnea. Over 150,000 users worldwide have reported easier breathing and improved quality of life. Used by both patients with chronic conditions and professional athletes.

Therapeutic areas: PulmonologyOther
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

West Ham United F.C. (professional athlete use/endorsement)European Federation of Allergy & Airways Diseases Patients’ Associations/EFA member collaboration for advocacy

Beyond the preview

Go deeper on WellO2.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WellO2.

Explore the full profile